Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
URL: http://antibodyregistry.org/AB_2893875
Proper Citation: Leinco Technologies Cat# LT1001, RRID:AB_2893875
Target Antigen: CD194
Host Organism: human
Clonality: recombinant monoclonal
Comments:
Applications: Depletion, ELISA, FA, FC
Info: This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only.
We found {{ ctrl2.mentions.all_count }} mentions in open access literature.
We have not found any literature mentions for this resource.
We are searching literature mentions for this resource.
Most recent articles:
{{ mention._source.dc.creators[0].familyName }} {{ mention._source.dc.creators[0].initials }}, et al. ({{ mention._source.dc.publicationYear }}) {{ mention._source.dc.title }} {{ mention._source.dc.publishers[0].name }}, {{ mention._source.dc.publishers[0].volume }}({{ mention._source.dc.publishers[0].issue }}), {{ mention._source.dc.publishers[0].pagination }}. (PMID:{{ mention._id.replace('PMID:', '') }})
A list of researchers who have used the resource and an author search tool
A list of researchers who have used the resource and an author search tool. This is available for resources that have literature mentions.
No rating or validation information has been found for Anti-Human CD194 (CCR4) (Mogamulizumab) - Biotin.
No alerts have been found for Anti-Human CD194 (CCR4) (Mogamulizumab) - Biotin.
Source: Antibody Registry
dkNET can assist you in preparing authentication plans for antibodies to comply with the NIH Submission Policy. The information can be used while planning your experiments or submitting grant applications. The authentication plan for antibodies is based on methods suggested in "A proposal for validation of antibodies" (Uhlen M et. al., 2016), the guideline published in the Journal of Comparative Neurology (Saper C, 2005)(2), and the example " Authentication of of Key Biological and/or Chemical Resources "(Bandrowski A). For best practices for authenticating antibodies, check our Authentication Reports services.